藥 名
永康
柳營
佳里
|
更新日期：04/24/2024 14:14:36
Dapagliflozin(10mg)錠.
|
現行藥品外觀
27D124
健保
自費
|
中文名：福適佳膜衣錠10毫克
健保碼：BC26476100
廠 牌：AstraZeneca
|
|
藥理分類
A10BK01
|
【Drugs used in diabetes】
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
|
|
|
藥理作用
|
|
|
Product name
|
Forxiga (10mg)錠.
|
|
Dosage form
|
Tab. 10 mg
|
|
Administration & Dosage
|
PO,
【Adult】
●Diabetes mellitus, type 2: Initial: 5 mg once daily; may increase to 10 mg once daily.
●Heart failure with reduced ejection fraction (adjunctive agent): 10 mg once daily.
●Chronic kidney disease (adjunctive agent): 10 mg once daily.
【Pediatric】
● Safety and efficacy not established in pediatric patients.
|
|
建議給藥途徑
|
N/A
|
|
腎功能劑量建議
|
eGFR < 25：Not recommended. HF&CKD: may continue 10 mg once daily.
eGFR 25-45：DM: not recommended. HF&CKD: No dosage adjustment necessary.
eGFR >45：No dosage adjustment necessary.
ESRD：Avoid use
Hemodialysis：Avoid use
|
|
肝功能劑量建議
|
Hepatic Impairment：No dosage adjustment necessary
|
|
Contraindication
|
History of serious hypersensitivity to dapagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or patients on dialysis.
|
|
Precaution
|
開始Forxiga前和治療期間應定期評估腎功能; urinary tract infection; bone fractures; genital mycotic infections; hypersensitivity reactions; hypotension;ketoacidosis; lipid abnormality; bladder cancer; hepatic impairment; renal impairment; elderly.
|
|
Adverse reaction
|
【1-10%】dyslipidemia; hyperphosphatemia; hypovolemia; nausea; fungal vaginosis, urinary tract infection, increased urine outpu, genitourinary fungal infections (mycotic; in males:,), dysuria; increased hematocrit; influenza; bone fracture, back pain, limb pain; nasopharyngitis.
【<1%】not referred here, please see package insert or other references.
【Unknown】increased LDL cholesterol; decreased estimated GFR (eGFR), increased serum creatinine
|
|
Pregnancy Category
|
C / 避免使用，除非有治療必要
|
|
Notes
|
|
|
相關連結
|
|
|
磨粉及剝半提示 |
無特別標註
|
|
給藥及保存方式 |
|
針劑相容溶液
*為文獻資料 |
|
| 健保給付規定 |
藥品說明：
理由1.TZD、DPP-4抑制劑、SGLT-2抑制劑、或含該成分之複方，限用於已接受過最大耐受劑量的metformin能無法理想控制血糖之DM type II。DPP-4抑制劑、SGLT-2抑制劑及其複方宜擇一使用。理由2.左心室收縮功能不全，左心室射出分率(LVEF)≦40%。
藥品理由：
01 已接受過最大耐受劑量的metformin仍無法理想控制血糖之第二型糖尿病患者
02 依NYHA分級為第二級至第四級之慢性收縮性心衰竭患者
03 經ACEI或ARB穩定治療，及合併β-block最大可耐受劑量已達4週以上或有禁忌症，仍有心衰竭症狀者
|
舊藥品外觀
|
中文名：福適佳膜衣錠10毫克
廠 牌：AstraZeneca
|